NUC-3373 for colorectal cancer

What is the Purpose of this Study?

We are doing this study to see if the study drug, NUC-3373, is safe and effective for treating colorectal cancer when combined with existing therapies.

What is the Condition Being Studied?

Colorectal Cancer

Who Can Participate in this Study?

Adults with colorectal cancer who:

- Have locally advanced, unresectable, or metastatic disease

- Have already received at least 1 line of treatment

For more information about who can join this study, please contact the study team at kelsey.conner@duke.edu.

Age Group

Adults

Participating Institutions

What is Involved?

If you choose to join this study, you will:

- Get NUC-3373 by IV every 1 or 2 weeks

- Get chemotherapy and/or bevacizumab every 2 weeks

- Give blood and urine samples

- Have regular CT or MRI scans

Study Details

Full Title

[Nutide302] A Phase Ib/II open label study to assess the safety and pharmacokinetics of NUC-3373, a nucleotide analogue, given in combination with standard agents used in colorectal cancer treatment

Principal Investigator

Niharika Mettu

Assistant Professor of Medicine

Protocol Number

IRB:

PRO00109258

NCT:

NCT03428958

ClinicalTrials.gov

View on ClinicalTrials.gov